Bliss GVS Pharma (506197) Q1 25/26 earnings summary

Executive summary

• Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, following a meeting on July 29, 2025.

• Financials prepared per Ind AS and reviewed by statutory auditors with unmodified conclusions.

Financial highlights

• Standalone revenue from operations for Q1 FY26 was ₹16,336.43 lakh, up from ₹14,896.29 lakh in Q1 FY25.

• Consolidated revenue from operations for Q1 FY26 was ₹20,746.92 lakh, up from ₹18,364.27 lakh in Q1 FY25.

• Standalone net profit for Q1 FY26 was ₹2,105.29 lakh, compared to ₹1,145.21 lakh in Q1 FY25.

• Consolidated net profit for Q1 FY26 was ₹4,303.79 lakh, compared to ₹2,069.74 lakh in Q1 FY25.

• Basic EPS (consolidated) for Q1 FY26 was ₹4.08, up from ₹1.97 in Q1 FY25.

Outlook and guidance

• No explicit forward-looking guidance provided, but results reflect continued growth in revenue and profitability year-over-year.